The Words to Actions initiative began in 2018, when nine organisations working in mental health across Europe (Eurocarers, European Brain Council, European College of Neuropsychopharmacology, European Federation of Associations of Families of People with Mental Illness (EUFAMI), European Psychiatric Association, Expert Platform on Mental Health Focus on Depression, Global Alliance of Mental Illness Advocacy Networks (GAMIAN-Europe), International Federation of Psychotherapy, Union Européenne des Médecins Spécialistes (UEMS) Section of Psychiatry) came together to develop and publish a policy report, A sustainable approach to depression: moving from words to actions.

This report was prepared by the group of experts listed as authors and contributors, with support from The Health Policy Partnership, a London-based health research consultancy. The authors had full editorial control over its content. The report was initiated and funded by Janssen Pharmaceutica NV (“Janssen”).

In 2019, the initiative continued with a standalone website developed by GAMIAN-Europe and The Health Policy Partnership. Building on the original policy report, Words to Actions released a series of five policy briefs and accompanying blog posts on key issues in depression.

In 2020, the @WTA_initiative Twitter account was launched to promote the initiative on social media. It was initiated and funded by Janssen, and its content developed by The Health Policy Partnership. Words to Actions released an animation, a series of digital posters and a Twitter campaign highlighting four overarching themes related to managing depression. The content was based on the original policy report.

In 2021, the initiative will continue to produce a new suite of materials in collaboration with leading mental health organisations from across Europe.

The Words to Actions initiative, including this website and all its contents, is initiated and funded by Janssen. The Health Policy Partnership produces all content in collaboration with other organisations (which are listed on the materials that they have co-developed). While Janssen has a right to review all content, editorial control rests with The Health Policy Partnership and collaborating organisations. None of the content is specific or biased to any particular treatment or therapy.